{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,22]],"date-time":"2026-06-22T13:37:58Z","timestamp":1782135478081,"version":"3.54.5"},"reference-count":11,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,6,18]]},"DOI":"10.7759\/cureus.62604","type":"journal-article","created":{"date-parts":[[2024,6,18]],"date-time":"2024-06-18T13:18:53Z","timestamp":1718716733000},"source":"Crossref","is-referenced-by-count":1,"title":["Severe Lactic Acidosis Due to Inappropriate Use of Biktarvy in a Patient With AIDS"],"prefix":"10.7759","author":[{"given":"Andrew","family":"Strike","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriel","family":"Velez Oquendo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarika","family":"Chowdry","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gurleen","family":"Kaur","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bcp.2023.115862","article-title":"Biktarvy for the treatment of HIV infection: progress and prospects","volume":"217","author":"De Clercq E","year":"2023","unstructured":"De Clercq E, Zhang Z, Huang J, Zhang M, Li G. Biktarvy for the treatment of HIV infection: progress and prospects. Biochem Pharmacol. 2023, 217:115862. 10.1016\/j.bcp.2023.115862","journal-title":"Biochem Pharmacol"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2024.107164","article-title":"Bictegravir\/emtricitabine\/tenofovir alafenamide as first-line treatment in na\u00efve HIV patients in a rapid-initiation model of care: BIC-NOW clinical trial","volume":"63","author":"Hidalgo-Tenorio C","year":"2024","unstructured":"Hidalgo-Tenorio C, Sequera S, Vivancos MJ, et al.. Bictegravir\/emtricitabine\/tenofovir alafenamide as first-line treatment in na\u00efve HIV patients in a rapid-initiation model of care: BIC-NOW clinical trial. Int J Antimicrob Agents. 2024, 63:107164. 10.1016\/j.ijantimicag.2024.107164","journal-title":"Int J Antimicrob Agents"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.19008","article-title":"Severe lactic acidosis due to acute intoxication by emtricitabine\/tenofovir alafenamide","volume":"13","author":"Chaparala S","year":"2021","unstructured":"Chaparala S, Da Silva RC, Papadopoulos JP. Severe lactic acidosis due to acute intoxication by emtricitabine\/tenofovir alafenamide. Cureus. 2021, 13:e19008. 10.7759\/cureus.19008","journal-title":"Cureus"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1111\/micc.12673","article-title":"Effects of impaired microvascular flow regulation on metabolism-perfusion matching and organ function","volume":"28","author":"Roy TK","year":"2021","unstructured":"Roy TK, Secomb TW. Effects of impaired microvascular flow regulation on metabolism-perfusion matching and organ function. Microcirculation. 2021, 28:e12673. 10.1111\/micc.12673","journal-title":"Microcirculation"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1016\/S1055-3290(06)60388-9","article-title":"Lactic acidosis associated with nucleoside reverse transcriptase inhibitors","volume":"11","author":"Caffrey PM","year":"2000","unstructured":"Caffrey PM. Lactic acidosis associated with nucleoside reverse transcriptase inhibitors. J Assoc Nurses AIDS Care. 2000, 11:91-95. 10.1016\/S1055-3290(06)60388-9","journal-title":"J Assoc Nurses AIDS Care"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1186\/cc2162","article-title":"Bench-to-bedside review: severe lactic acidosis in HIV patients treated with nucleoside analogue reverse transcriptase inhibitors","volume":"7","author":"Claessens YE","year":"2003","unstructured":"Claessens YE, Chiche JD, Mira JP, Cariou A. Bench-to-bedside review: severe lactic acidosis in HIV patients treated with nucleoside analogue reverse transcriptase inhibitors. Crit Care. 2003, 7:226-32. 10.1186\/cc2162","journal-title":"Crit Care"},{"key":"ref7","doi-asserted-by":"crossref","DOI":"10.5812\/ircmj.19546","article-title":"Fatal tenofovir-associated lactic acidosis: a case report","volume":"17","author":"Hashim H","year":"2015","unstructured":"Hashim H, Sahari NS, Sazlly Lim SM, Hoo FK. Fatal tenofovir-associated lactic acidosis: a case report. Iran Red Crescent Med J. 2015, 17:e19546.","journal-title":"Iran Red Crescent Med J"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1016\/s0248-8663(02)00702-6","article-title":"Severe lactic acidosis in HIV-infected patients treated with nucleosidic reverse transcriptase analogs: a report of 9 cases (Article in French)","volume":"24","author":"Bonnet F","year":"2003","unstructured":"Bonnet F, Bonarek M, Abridj A, et al.. Severe lactic acidosis in HIV-infected patients treated with nucleosidic reverse transcriptase analogs: a report of 9 cases (Article in French). La Revue de M\u00e9decine Interne. 2003, 24:11-16. 10.1016\/s0248-8663(02)00702-6","journal-title":"La Revue de M\u00e9decine Interne"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1089\/1087291041518229","article-title":"Prognostic factors in lactic acidosis syndrome caused by nucleoside reverse transcriptase inhibitors: report of eight cases and review of the literature","volume":"18","author":"Tripuraneni NS","year":"2004","unstructured":"Tripuraneni NS, Smith PR, Weedon J, Rosa U, Sepkowitz D. Prognostic factors in lactic acidosis syndrome caused by nucleoside reverse transcriptase inhibitors: report of eight cases and review of the literature. AIDS Patient Care STDS. 2004, 18:379-84. 10.1089\/1087291041518229","journal-title":"AIDS Patient Care STDS"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1186\/s12981-021-00382-8","article-title":"Lactic acidosis and hyperlactatemia associated with lamivudine accumulation and sepsis in a kidney transplant recipient-a case report and review of the literature","volume":"18","author":"Hollinger A","year":"2021","unstructured":"Hollinger A, Cueni N, Marzolini C, et al.. Lactic acidosis and hyperlactatemia associated with lamivudine accumulation and sepsis in a kidney transplant recipient-a case report and review of the literature. AIDS Res Ther. 2021, 18:56. 10.1186\/s12981-021-00382-8","journal-title":"AIDS Res Ther"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1093\/ajhp\/zxac339","article-title":"Utilization of bictegravir\/emtricitabine\/tenofovir alafenamide in patients with end-stage renal disease on hemodialysis","volume":"80","author":"Sidman EF","year":"2023","unstructured":"Sidman EF, Ondrush NM. Utilization of bictegravir\/emtricitabine\/tenofovir alafenamide in patients with end-stage renal disease on hemodialysis. Am J Health Syst Pharm. 2023, 80:e92-7. 10.1093\/ajhp\/zxac339","journal-title":"Am J Health Syst Pharm"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/263900-severe-lactic-acidosis-due-to-inappropriate-use-of-biktarvy-in-a-patient-with-aids","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,18]],"date-time":"2024-06-18T13:18:56Z","timestamp":1718716736000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/263900-severe-lactic-acidosis-due-to-inappropriate-use-of-biktarvy-in-a-patient-with-aids"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6,18]]},"references-count":11,"URL":"https:\/\/doi.org\/10.7759\/cureus.62604","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2024,6,18]]}}}